3Neeltje Steeghs MD,Johan W. R. Nortier MD, PhD,Hans Gelderblom MD, PhD. Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments[J] 2007,Annals of Surgical Oncology(2):942～953
4Mendelsohn J,Baselga J.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol,2003,21(14):2787～2799.
5Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].J Am Med Assoc,2003,290(16):2149～2158.
6Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003,21(12):2237～2246.
7Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer:a phase Ⅲ trial-INTACT 1[J].J Clin Oncol,2004,22(5):777～784.
8Herbst RS,Giaccone G,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT 2[J].J Glin Oncol,2004,22 (5):785 ～ 794.
9Xu JM,Azzariti A,Colucci G,et al.The effect of gefitinib (Iressa,zd1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines[J].Cancer Chemother Pharmacol,2003,52(6):442～ 448.
10Xu JM,Paradiso A,McLeod HL,et al.Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy:Is there a need for a more rational design[J]? Eur J Cancer,2004,40(12):1807～1809.
